RadMD welcomes Rendon Nelson to the team
RadMD would like to extend a warm welcome to Rendon Nelson, MD, who has joined us as Director of medical and scientific affairs. Rendon was tenured Professor of Radiology at Duke University, serving in numerous administrative roles including the…
BICR Reader Training Practices that enable Best Performance
You are invited to an interactive RadMD Webinar - BICR Reader Training Practices to ensure Best Performance Presenter: Dr. Rick Patt, RadMD Co-founder and Panelist: Dr. Rendon Nelson, RadMD Medical Director During this webinar, members of…
Co-Founder Dr Kohkan Shamsi confirmed as RSNA 2022 speaker
Dr Kohkan Shamsi, RadMD co-founder, has been confirmed as a speaker for RSNA 2022 Dr Shamsi is booked to discuss “The Effect of Food Intake on Pharmacodynamics of A Novel Oral Liver-specific Contrast Agent: Orviglance (Manganese Chloride…
Clinical Evidence Supports Dotarem® Injection for MR Imaging
New Article in Applied Radiology, the Journal of Practical Medical Imaging and Management: Magnetic resonance imaging (MRI) contrast agents are widely used to increase the contrast difference between normal and abnormal tissues. Also known as…
RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent
RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent to assess somatostatin receptor (SSTR2) positive gastroenteropancreatic neuroendotrine tumor (GEP-NET) that employed novel independent read…
Kohkan Shamsi, in collaboration with ICPME, develops an accredited course
Kohkan Shamsi, in collaboration with ICPME, develops an accredited course intended to educate on the potential implications of ordering and performing contrast-enhanced MRIs The use of gadolinium-based contrast agents in MR imaging has been…
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease:
A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation both in…
JAMA Article on Gadolinium Exposure and Parkinson’s: A False Sense of Safety?
Welk B, McArthur E, Marrow SA, et al. Association between Gadolinium contrast Exposure and the Risk of Parkinsonism Dr. Welk and colleagues conducted a retrospective review of multiple linked administrative databases from Ontario, Canada to evaluate…
Deposition of Gadolinium in After Multiple GBCA Injections: Clinical Trial Prospective
Gadolinium-based contrast agents (GBCAs) are indispensable adjuncts to MRI, with numerous studies showing their efficacy in improving the accuracy of MRI studies. Gadolinium deposition in the brains of patients who received multiple doses of GBCAs…
RSNA 2014 Abstract: Evaluation of a New Manganese-based Orally-Administered Hepatobiliary MR Contrast Agent
To read the full article —>